samedan logo
 
 
spacer
home > epc > spring 2008 > voicing concerns
PUBLICATIONS
European Pharmaceutical Contractor

Voicing Concerns

Claudia Horneck at clinIT AG looks at implementing interactive voice response systems for more effective randomisation of patents for clinical trials

The implementation of an interactive voice response system (IVRS) has proven useful in a wide range of study settings. Some obvious advantages of such a system include active patient involvement, centrally-performed treatment allocation, and the creation of a direct link with drug supply management. These virtues of IVRS interact closely with other study-relevant aspects such as statistics, project management, data management, drug supply management and safety. To arrange the interfaces between IVRS and these domains in the best way possible, questions that should be considered include: the points at which interaction occurs; the information being exchanged; which problems might arise under certain circumstances; and the factors determining the quality of data, time and cost.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Claudia Horneck is the Marketing Director of clinIT AG, but also works as a self-employed Consultant working closely with pharmaceutical contract research organisations. She received her Masters in German Literature, Linguistics and Philosophy from the Albert-Ludwigs University, Freiburg, Germany. Prior to her position at clinIT AG, Claudia held the positions of Head of Sales Administration and Customer Relations Manager at Thomae & Partner AG, Freiburg.
spacer
Claudia Horneck
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials

HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement